Ironwood Pharmaceuticals (IRWD) Cost of Revenue (2013 - 2020)

Ironwood Pharmaceuticals has disclosed Cost of Revenue across 7 years of filings, most recently posting $897000.0 for Q4 2020.

• Cost of Revenue for Q4 2020 came in at $897000.0, down 91.86% year-over-year; the trailing twelve-month figure through Dec 2020 was $3.1 million (down 86.86% YoY), and the FY2020 annual result was $3.1 million, down 86.86% from the prior year.
• Cost of Revenue came in at $897000.0 for Q4 2020 at Ironwood Pharmaceuticals, down from $2.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $21.5 million in Q4 2018 to a low of $506000.0 in Q3 2019.
• The 4-year median for Cost of Revenue is $3.8 million (2017), against an average of $5.6 million.
• Across the five-year window, Cost of Revenue soared 390.96% in 2018 and slumped 91.86% in 2020, its largest moves.
• Ironwood Pharmaceuticals' Cost of Revenue stood at $9.0 million in 2017, then surged by 138.9% to $21.5 million in 2018, then tumbled by 48.69% to $11.0 million in 2019, then plunged by 91.86% to $897000.0 in 2020.
• The last three Cost of Revenue figures came in at $897000.0 (Q4 2020), $2.2 million (Q1 2020), and $11.0 million (Q4 2019), per Business Quant data.